Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

John S. Kim; Yifei Sun; Pallavi Balte; Mary Cushman; Rebekah Boyle; Russell P. Tracy; Linda M. Styer; Taison D. Bell; Michaela R. Anderson; Norrina B. Allen; Pamela Schreiner; Russell P. Bowler; David A. Schwartz; Joyce S. Lee; Vanessa Xanthakis; Margaret F. Doyle; Elizabeth A. Regan; Barry J. Make; Alka M. Kanaya; Sally E. Wenzel; Josef Coresh; Carmen R. Isasi; Laura M. Raffield; Mitchell S.V. Elkind; Virginia J. Howard; Victor E. Ortega; Prescott Woodruff; Shelley A. Cole; Joel M. Henderson; Nicholas J. Mantis; Monica M. Parker; Ryan T. Demmer; Elizabeth C. Oelsner

doi:10.1038/s41467-024-45468-9

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

John S. Kim, Yifei Sun, Pallavi Balte, Mary Cushman, Rebekah Boyle, Russell P. Tracy, Linda M. Styer, Taison D. Bell, Michaela R. Anderson, Norrina B. Allen, Pamela Schreiner, Russell P. Bowler, David A. Schwartz, Joyce S. Lee, Vanessa Xanthakis, Margaret F. Doyle, Elizabeth A. Regan, Barry J. Make, Alka M. Kanaya, Sally E. WenzelJosef Coresh, Carmen R. Isasi, Laura M. Raffield, Mitchell S.V. Elkind, Virginia J. Howard, Victor E. Ortega, Prescott Woodruff, Shelley A. Cole, Joel M. Henderson, Nicholas J. Mantis, Monica M. Parker, Ryan T. Demmer, Elizabeth C. Oelsner

Epidemiology

Research output: Contribution to journal › Article › peer-review

Abstract

This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.

Original language	English (US)
Article number	1492
Journal	Nature communications
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41467-024-45468-9
State	Published - Dec 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

PubMed: MeSH publication types

Journal Article

Access

10.1038/s41467-024-45468-9

OpenUrl availability

Full text

Cite this

Kim, J. S., Sun, Y., Balte, P., Cushman, M., Boyle, R., Tracy, R. P., Styer, L. M., Bell, T. D., Anderson, M. R., Allen, N. B., Schreiner, P., Bowler, R. P., Schwartz, D. A., Lee, J. S., Xanthakis, V., Doyle, M. F., Regan, E. A., Make, B. J., Kanaya, A. M., ... Oelsner, E. C. (2024). Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study. Nature communications, 15(1), Article 1492. https://doi.org/10.1038/s41467-024-45468-9

Kim, JS, Sun, Y, Balte, P, Cushman, M, Boyle, R, Tracy, RP, Styer, LM, Bell, TD, Anderson, MR, Allen, NB, Schreiner, P, Bowler, RP, Schwartz, DA, Lee, JS, Xanthakis, V, Doyle, MF, Regan, EA, Make, BJ, Kanaya, AM, Wenzel, SE, Coresh, J, Isasi, CR, Raffield, LM, Elkind, MSV, Howard, VJ, Ortega, VE, Woodruff, P, Cole, SA, Henderson, JM, Mantis, NJ, Parker, MM, Demmer, RT & Oelsner, EC 2024, 'Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study', Nature communications, vol. 15, no. 1, 1492. https://doi.org/10.1038/s41467-024-45468-9

@article{27776715521b40d29e82b37f89e9917c,

title = "Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study",

abstract = "This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.",

author = "Kim, {John S.} and Yifei Sun and Pallavi Balte and Mary Cushman and Rebekah Boyle and Tracy, {Russell P.} and Styer, {Linda M.} and Bell, {Taison D.} and Anderson, {Michaela R.} and Allen, {Norrina B.} and Pamela Schreiner and Bowler, {Russell P.} and Schwartz, {David A.} and Lee, {Joyce S.} and Vanessa Xanthakis and Doyle, {Margaret F.} and Regan, {Elizabeth A.} and Make, {Barry J.} and Kanaya, {Alka M.} and Wenzel, {Sally E.} and Josef Coresh and Isasi, {Carmen R.} and Raffield, {Laura M.} and Elkind, {Mitchell S.V.} and Howard, {Virginia J.} and Ortega, {Victor E.} and Prescott Woodruff and Cole, {Shelley A.} and Henderson, {Joel M.} and Mantis, {Nicholas J.} and Parker, {Monica M.} and Demmer, {Ryan T.} and Oelsner, {Elizabeth C.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41467-024-45468-9",

language = "English (US)",

volume = "15",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults

T2 - the C4R Study

AU - Kim, John S.

AU - Sun, Yifei

AU - Balte, Pallavi

AU - Cushman, Mary

AU - Boyle, Rebekah

AU - Tracy, Russell P.

AU - Styer, Linda M.

AU - Bell, Taison D.

AU - Anderson, Michaela R.

AU - Allen, Norrina B.

AU - Schreiner, Pamela

AU - Bowler, Russell P.

AU - Schwartz, David A.

AU - Lee, Joyce S.

AU - Xanthakis, Vanessa

AU - Doyle, Margaret F.

AU - Regan, Elizabeth A.

AU - Make, Barry J.

AU - Kanaya, Alka M.

AU - Wenzel, Sally E.

AU - Coresh, Josef

AU - Isasi, Carmen R.

AU - Raffield, Laura M.

AU - Elkind, Mitchell S.V.

AU - Howard, Virginia J.

AU - Ortega, Victor E.

AU - Woodruff, Prescott

AU - Cole, Shelley A.

AU - Henderson, Joel M.

AU - Mantis, Nicholas J.

AU - Parker, Monica M.

AU - Demmer, Ryan T.

AU - Oelsner, Elizabeth C.

PY - 2024/12

Y1 - 2024/12

N2 - This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.

AB - This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85185513955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185513955&partnerID=8YFLogxK

U2 - 10.1038/s41467-024-45468-9

DO - 10.1038/s41467-024-45468-9

M3 - Article

C2 - 38374032

AN - SCOPUS:85185513955

SN - 2041-1723

VL - 15

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 1492

ER -

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

Abstract

Bibliographical note

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this